

Domain Therapeutics collaborates with Boehringer Ingelheim

05 December 2018 | News

Domain will be eligible for an upfront payment, discovery, development and commercial milestone payments as well as royalties on sales



Pharma company, Domain Therapeutics has announced a multi-target drug discovery collaboration and licensing agreement with Boehringer Ingelheim on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area.

The collaboration combines the expertise of Domain Therapeutics in the discovery of GPCR targeting drugs in CNS, oncology and immuno-oncology, with Boehringer Ingelheim's expertise in the discovery and clinical development of therapeutics on multiple indications.

Domain Therapeutics will use its proprietary platforms, DTect-All™ and bioSens-All™, which enable a comprehensive characterization of small molecule GPCR binders for the screening and characterization of potential lead compounds.

Dr Bernd Sommer, Global Head, CNS Diseases Research said, "We are excited to initiate the collaboration with Domain Therapeutics, a leading player in the GPCR space. This collaboration helps us to bolster our CNS research efforts. We have a valuable partner with complementary expertise and key technologies that allow us to accelerate research and development in this area of great unmet medical need."

Pascal Neuville, CEO of Domain Therapeutics said, "With its focus on emerging science and breakthrough medicines, we are enthusiastic to be working with Boehringer Ingelheim. We believe that our approach and technologies will allow for the identification of new drug candidates against these challenging targets, and, coupled with Boehringer Ingelheim's strength and expertise, their rapid advancement into the clinic."

Domain will be eligible for an upfront payment, discovery, development and commercial milestone payments as well as royalties on sales. Financial details are not disclosed.

